Liquid Biopsy Market Will Be Worth $5.96 Billion By 2030: Grand View Research, Inc.
Global liquid biopsies market is anticipated to reach
5,958.3 million by 2030, according to a new report by Grand View Research, Inc.
As these less invasive biopsies are able to address a number of significant
challenges associated with conventional biopsies such as, high level of
invasiveness, incompleteness of cancer information that is acquired, associated
post-biopsy serious medical complications, and subsequent cost inclusions. A
growing need for more advanced, efficient and accurate method which provides a
holistic view of the tumor and metastasis is the prime factor fueling rapid
development of liquid biopsies.
The market has gained
considerable traction in the past couple of years. A number of clinical
research projects related to circulating tumor cells, and cell-free tumor DNA
have been initiated in the latter half of the past decade. As a result, there
are a number of ongoing clinical trials that are due to be completed between
post 2017-18. It is expected that upon successful completion, commercialization
of these assays and tests will provide the market a significant boost in
potential addressable target revenue and fuel growth through to 2030.
Browse full research report on Liquid Biopsy Market: http://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Further key findings from
the report suggest:
- In terms of applications, therapy selection of
metastatic cancers is the key area of liquid biopsy usage as these provide
significant insights into the unique genetic information encoded in CTCs
and ctDNAs. Furthermore, with the addition of more research data
reinforcing the usage of liquid biopsies over the coming years, it is
expected that their application for molecular monitoring of diseases will
also be a lucrative source of revenue through to 2030
- Key biomarkers that any liquid biopsy targets include
circulating tumor cells, circulating tumor DNA and exosomes that are
macrovesicles containing tumor RNA, or tumor protein freely circulating in
the patient’s bloodstream. Assays for ctDNA are expected to account for
the largest share of revenue through to 2030 owing to the currently
present assays and expected number of products that are to be
commercialized over the coming decade.
- Development of parallel multi-gene analysis using
next generation sequencing technology is the underlying factor that has
enabled oncologists to more efficiently sequence ctDNA and gain insights
related to cancer metastasis and the related mechanism. This understanding
provides a patient-centric systemic view of cancer and aids in its long
term monitoring.
- North America, specifically the U.S. accounts for the
largest share of revenue for the development of liquid biopsy market. The
region was observed to account for around 50% of the global potential in
2015 owing to the high number clinical development projects underway for
the commercialization of CTC and ctDNA assays till 2020. Furthermore,
throughout the forecast period, U.S. is expected to dominate revenue
generation owing to the dynamic nature & being the region of prime
activity, research and development with respect to liquid biopsy and next
generation sequencing technology.
- Although, post successful commercialization through
to 2030, Asia Pacific is expected to be a lucrative region for development
as it is expected to be characterized by the presence of a large patient
population base, developing healthcare framework and growth in integration
of more advanced healthcare practices.
- The market is in its developing phase and is
characterized by the presence of a number of relatively smaller entities
involved in innovation and new product development. Companies such as
Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant
Health, Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance
Technologies, and Trovagene are operating in the space and have a number
of commercialized assays in their portfolios for liquid biopsy.
- Furthermore, as this space has a high lucrative
potential, and is considerably influenced by the developments in NGS
technology, there are a number of major players that have ongoing
investigational & observational clinical trials and are due to be
completed by 2017 to 2019. Collectively, over 30 clinical trials are
currently registered as active by companies including Illumina, Foundation
Medicine, Natera Inc., Roche, Sequenom, LabCorp, Epic Sciences, and
Pathway Genomics in the U.S. alone. Anticipated successful
commercialization of these products is expected to fuel growth over the
forecast period.
Browse more reports of this category by Grand View
Research : http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the liquid biopsy market
on the basis of application, sample type, biomarker, technology, and region:
Global Liquid Biopsy Outlook, by Application (Revenue,
USD Million, 2013 - 2030)
- Therapy
Selection for Metastatic Breast Cancer (MBS)
- Therapy
Selection for Other Metastatic Cancer
- Molecular
Health Monitoring
Global Liquid Biopsy, by Sample Type (Revenue, USD
Million, 2013 - 2030)
- Blood
Sample based
- Urine
Sample based
- Other
Bio Fluids (Tissue fluids and Saliva) based
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
- Circulating
Tumor Cells (CTC)
- Circulating
Tumor DNA (ctDNA)
- Exosomes
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
- Multi
- gene - parallel Analysis (NGS)
- Single
Gene Analysis (PCR Microarrays)
Global Liquid Biopsy Market, Regional Outlook (Revenue,
USD Million, 2013 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Brazil
- MEA
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare
.
Comments
Post a Comment